ISSCR News
The ISSCR Shares Comments on the European Medicines Agency's Network Strategy to 2025
The ISSCR shared comments with the European Medicines Agency (EMA) related to its Network Strategy 2025. This included support for the crucial role of EMA and national regulators in overseeing the development of new products and offer a few recommendations to ensure that new products are proven safe and effective before being marketed to patients.
ISSCR Applauds Australia’s Move to Regulate Autologous Human Cell and Tissue Products
The ISSCR appreciates the new framework proposed by Australia’s Therapeutic Goods Administration (TGA) for the regulation of human cell and tissue products that use a person’s own cells (‘autologous use’). These new regulations are meant to halt the marketing and administration of unproven cell therapies that have not been proven safe or effective. Sales of these products by unscrupulous clinics to desperate patients have been increasing in recent years. Recently, these products resulted in the death of an Australian patient and the blinding of three patients in the United States.
ISSCR Advocates for Stem Cells and Basic Research in Europe
The ISSCR met 11 April with the European Parliament’s Committee on Industry, Research and Energy to advocate for investments in basic research in the European Union’s 9th Framework Programme for Research and Innovation. ISSCR members Pete Coffey and Michele De Luca, along with ISSCR Policy Director Eric Anthony, described the need for continued investments in basic research to improve understanding of human physiology and develop new approaches to treat disease.
ISSCR Advocates for Science Investment in Letter to European Commission
In a letter to the European Commission today, the ISSCR encourages the EU to spur innovation by supporting basic research and programs that foster cooperation among fundamental research endeavors across Europe. "Sustained investments in fundamental research will stimulate innovation-led growth for years to come," according to the letter, signed by ISSCR president Hans Clevers.
'Right to Try' Legislation in U.S. House of Representatives is Narrowly Defeated; ISSCR Opposed
On 12 March, a day before a vote in the U.S. House of Representatives on 'Right to Try' legislation, the ISSCR wrote a letter to House leadership expressing opposition to the measure, which would have allowed patients access to experimental medical treatments without FDA oversight and approval. The measure was narrowly defeated 13 March.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .